2021
ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody
Rattray Z, Deng G, Zhang S, Shirali A, May CK, Chen X, Cuffari BJ, Liu J, Zou P, Rattray N, Johnson CH, Dubljevic V, Campbell JA, Huttner A, Baehring JM, Zhou J, Hansen JE. ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody. JCI Insight 2021, 6: e145875. PMID: 34128837, PMCID: PMC8410084, DOI: 10.1172/jci.insight.145875.Peer-Reviewed Original ResearchConceptsBlood-brain barrierAnti-DNA autoantibodiesBrain tumorsBreast cancer brain metastasesBlood-brain barrier transportBrain tumor immunotherapyCancer brain metastasesBrain endothelial cellsEndothelial cell penetrationCNS lupusNeurotoxic autoantibodiesBrain metastasesTumor immunotherapyBarrier transportAntibody-based approachesCNS penetrationAutoantibodiesEfficacy studiesOrthotopic glioblastomaEndothelial cellsTumorsCancer cellsNucleoside fluxesActionable mechanismsKey transporters
2018
Re-engineering and evaluation of anti-DNA autoantibody 3E10 for therapeutic applications
Rattray Z, Dubljevic V, Rattray NJW, Greenwood DL, Johnson CH, Campbell JA, Hansen JE. Re-engineering and evaluation of anti-DNA autoantibody 3E10 for therapeutic applications. Biochemical And Biophysical Research Communications 2018, 496: 858-864. PMID: 29374508, DOI: 10.1016/j.bbrc.2018.01.139.Peer-Reviewed Original Research
2016
A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors
Chen Z, Patel JM, Noble PW, Garcia C, Hong Z, Hansen JE, Zhou J. A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors. Oncotarget 2016, 7: 59965-59975. PMID: 27494868, PMCID: PMC5312362, DOI: 10.18632/oncotarget.11015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, AntinuclearAntibodies, CatalyticBreast NeoplasmsCell Line, TumorDNADoxorubicinDrug Delivery SystemsFemaleHumansLactic AcidLupus Coagulation InhibitorMammary Neoplasms, AnimalMiceMice, Inbred BALB CNanoparticlesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerTumor MicroenvironmentConceptsDelivery of nanoparticlesDOX-loaded nanoparticlesTumor-targeting mechanismDrug delivery mechanismsAmount of moleculesNanoparticle deliveryLupus anti-DNA autoantibodiesNanoparticlesProof of conceptRelease of DNASurface modificationBind moleculesAutocatalytic effectDelivery mechanismTumor neovasculatureMoleculesDeliveryDoxorubicinTumor microenviromentMajor limitationEfficiencyLigandsSubsequent treatmentToxic agentsDNADNA-damaging autoantibodies and cancer: the lupus butterfly theory
Noble PW, Bernatsky S, Clarke AE, Isenberg DA, Ramsey-Goldman R, Hansen JE. DNA-damaging autoantibodies and cancer: the lupus butterfly theory. Nature Reviews Rheumatology 2016, 12: 429-434. PMID: 27009542, DOI: 10.1038/nrrheum.2016.23.Peer-Reviewed Original ResearchAntibodies, AntinuclearAutoantibodiesAutoimmunityBiomarkersDNA DamageHumansLupus Erythematosus, SystemicNeoplasms
2015
DNA-dependent targeting of cell nuclei by a lupus autoantibody
Weisbart RH, Chan G, Jordaan G, Noble PW, Liu Y, Glazer PM, Nishimura RN, Hansen JE. DNA-dependent targeting of cell nuclei by a lupus autoantibody. Scientific Reports 2015, 5: 12022. PMID: 26156563, PMCID: PMC4496662, DOI: 10.1038/srep12022.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, AntinuclearAutoantibodiesCell Line, TumorCell NucleusDNAHumansLupus Erythematosus, SystemicProtein TransportSingle-Chain AntibodiesConceptsLupus anti-DNA autoantibodiesAnti-DNA autoantibodiesTumor cell nucleiSingle-chain variable fragmentPotential therapeutic applicationsLupus autoantibodiesTherapeutic approachesIschemic conditionsCertain cancer cellsChain variable fragmentCancer cellsCell nucleiAutoantibodiesNecrotic regionsVariable fragmentTherapeutic applicationsDNA damageNuclear uptakeScFvMalignancyGreater understandingTumorsStrokeDiseaseOptimizing a Lupus Autoantibody for Targeted Cancer Therapy
Noble PW, Chan G, Young MR, Weisbart RH, Hansen JE. Optimizing a Lupus Autoantibody for Targeted Cancer Therapy. Cancer Research 2015, 75: 2285-2291. PMID: 25832653, DOI: 10.1158/0008-5472.can-14-2278.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, AntinuclearDNA Breaks, Double-StrandedHCT116 CellsHumansLupus Erythematosus, SystemicNeoplasmsRecombinant Proteins
2014
A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells
Noble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Scientific Reports 2014, 4: 5958. PMID: 25091037, PMCID: PMC5380011, DOI: 10.1038/srep05958.Peer-Reviewed Original ResearchConceptsLupus autoantibodiesTherapeutic agentsCancer cellsSystemic lupus erythematosusBRCA2-deficient cellsLupus erythematosusBRCA2-deficient cancer cellsDLD1 colon cancer cellsColon cancer cellsSuch antibodiesLower riskAutoantibodiesSpecific cancersAntibodiesMalignancyDifferential effectsToxic effectsPotential utilityCellsAgentsFurther supportDNA-damaging agentsErythematosusTherapyCancer